Dr. George on Critical Clinical Trials in Kidney Cancer OncLive ... MD, Director, GU Oncology, Duke Cancer Institute, discusses critical phase III clinical trials in metastatic renal cell carcinoma (mRCC). The ADAPT study, George says, is looking at patients with newly diagnosed mRCC who have undergone a nephrectomy. |
